GenSight Biologics, a biopharma company specializing in gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has announced its financial calendar for 2024. The company, listed on Euronext under the ticker symbol SIGHT, revealed key dates for investors and stakeholders to mark on their calendars.
The first event on the financial calendar is the disclosure of the 2024 1Q Cash Position, scheduled for April 4, 2024. This will be followed by the Annual General Meeting on May 29, 2024, where important decisions and updates will be shared with shareholders.
In addition, GenSight Biologics will provide an update on its 2024 2Q Cash Position on July 23, 2024, followed by the release of the 2024 First-Half Financial Update and Statements on September 23, 2024. The company will then disclose its 2024 3Q Cash Position on October 24, 2024.
The financial calendar serves as a roadmap for investors and analysts to stay informed about the company’s financial health and performance throughout the year. It provides transparency and accountability, allowing stakeholders to make informed decisions based on the company’s financial outlook.
GenSight Biologics is known for its innovative gene therapies aimed at preserving or restoring vision in patients with retinal diseases. The company’s lead product candidate, LUMEVOQ® (GS010), is designed to treat Leber Hereditary Optic Neuropathy, a rare mitochondrial disease that causes irreversible blindness.
Investors and stakeholders can access the updated financial calendar on GenSight Biologics’ corporate website for any changes or additional information. Stay tuned for more updates on this groundbreaking biopharma company’s financial performance in 2024.